The study found that the Sofosbuvir/daclatasvir combination achieved an 81.6% SVR4 rate after 12 weeks of treatment and a 93.9% SVR4 rate after 24 weeks, with a 100% SVR4 rate when combined with ribavirin. The treatment was effective in both cirrhotic and non-cirrhotic patients.
A worldwide study shows that daily drinking is a significant predictor of liver disease burden, with heavy drinkers having the highest risk. The study highlights the need for reducing heavy drinking as an important target for public health monitoring and policies.
A new study presented at The International Liver Congress 2015 showed high rates of sustained virologic response and good tolerance when using sofosbuvir and daclatasvir-based regimens in patients with recurrent hepatitis C. These results support the use of interferon-free regimens in managing liver transplant patients infected with HCV.
A comprehensive review highlights the need for better evidence on hepatitis B and C testing in European countries. The study found gaps in knowledge, particularly for high-risk populations such as migrants and men who have sex with men.
A Phase 3 study demonstrates that sofosbuvir in combination with ribavirin and peginterferon is highly effective for treating genotype-3 HCV-infected patients, particularly those with cirrhosis. The BOSON study shows the optimal duration of treatment for these patients, which could lead to improved outcomes.
The RUBY-1 study evaluates ombitasvir/paritaprevir/ritonavir and dasabuvir in patients with stage 4 or 5 CKD and HCV GT1 infection, revealing a well-tolerated combination with rapid viral load suppression.
A study reveals that individuals with undiagnosed hepatitis C infection have a similar risk of developing advanced liver fibrosis as those who are diagnosed. The findings support the importance of regular screening for HCV, especially in high-risk groups.
A 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir is effective and well-tolerated in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6. Preliminary results show that 299 out of 316 patients achieved a sustained virologic response at 12 weeks.
The study demonstrated that ledipasvir-sofosbuvir achieves high sustained virologic response rates in patients with chronic genotype 4 and 5 HCV infection. The treatment was found to be effective in both treatment-naive and treatment-experienced patients, with similar SVR12 rates across all patient types.
BLU-554, a small molecule inhibitor of FGFR4, has been identified as a potential treatment option for up to 30% of HCC patients. The investigational drug was shown to be potent and 'exquisitely selective' for FGFR4 compared to other kinases targeting the FGFR family.
A large population-based cohort study found that non-alcoholic steatohepatitis (NASH) increases the risk of death by 50% compared to non-alcoholic fatty liver disease (NAFLD). The study also showed that patients with NASH had a higher risk of cardiovascular disease and all-cause mortality over a 14-year period.
Researchers discovered that cancer rates among hepatitis C patients are significantly higher than those without the virus. The study found a 2.5 times higher rate of all cancers and almost twice as high when liver cancer is excluded.
Results from the SOLAR 2 trial show that ledipasvir/sofosbuvir in combination with ribavirin is safe and effective in patients with decompensated liver disease or who have undergone liver transplantation. High sustained virologic response rates were achieved, even among treatment-experienced patients.
The HCV-TARGET study shows all-oral direct-acting antiviral therapy is highly effective and well tolerated in patients with decompensated cirrhosis, with SVR rates of 75%, 77% and 81%. Liver function markers also improve during short-term follow-up.
A pooled analysis of data from two randomized trials confirms vitamin E as an effective treatment for non-alcoholic steatohepatitis (NASH), with significant improvements in liver histology and disease resolution. The study supports the use of vitamin E as a safe and effective solution for both adults and children with NASH.
Researchers found that delaying treatment until after a patient's FIB4 level exceeds 3.25 has a clear detrimental effect on treatment effectiveness, increasing morbidity and mortality risks. Early treatment initiation is crucial to prevent adverse outcomes.
A new study published at The International Liver Congress reveals that non-alcoholic fatty liver disease (NAFLD) is associated with the development of coronary artery calcification. In patients without existing CAC, NAFLD significantly accelerated atherosclerosis progression, while in those with existing CAC, it did not affect disease ...
Scaling up existing interventions, including infant vaccination and treatment programmes, could prevent 90% of new chronic HBV infections and 65% mortality levels by 2030. Global expansion is necessary to achieve hepatitis B elimination, avoiding 20 million deaths by 2030.
Researchers identified specific molecular profiles and mutational patterns that can help determine which hepatocellular carcinoma patients benefit from targeted anticancer treatments. The study suggests that exome sequencing can be used to identify potential new targets for therapy, leading to optimized personalized patient care.
A new study at The International Liver Congress 2015 reveals that sofosbuvir-based regimens are effective and well-tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response was observed in 98% of patients at 4 weeks and 95% at 12 weeks.
A new study reveals that chronic hepatitis C virus (HCV) infection is associated with a higher risk of developing cardiovascular diseases. The study found significant increases in the cost of care and length of time in hospital for patients with HCV infections.
Capsaicin, the active compound in chili peppers, has been found to have beneficial effects on liver damage. In a study, capsaicin reduced the activation of hepatic stellate cells, which are involved in liver fibrosis. The compound partially improved liver damage and inhibited further progression of the injury in mice models.
A new device has demonstrated its potential to preserve and improve the quality of donor livers from donation after circulatory death (DCD) for transplantation. The transportable machine perfusion Airdrive effectively maintained liver quality, reducing biliary complications and increasing graft function.
Remogliflozin etabonate improves insulin sensitivity and beta cell function, reducing ALT levels and weight in patients with NASH. The investigational drug also exhibits intrinsic anti-oxidant activity, reversing steatohepatitis and oxidative stress.
A randomized controlled trial demonstrated liraglutide met the primary endpoint of histological clearance of non-alcoholic steatohepatitis, and a reduction in fibrosis progression. The study also showed significant weight loss, BMI reduction, and fasting glucose decrease with liraglutide treatment.
A study has demonstrated that alginate-enriched bread can inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD). The results show a significant reduction of up to 31% in fat digestion, suggesting its potential use as a therapeutic weight management therapy.
A new study shows that Baclofen has a positive impact on alcohol consumption and liver function in patients with alcohol-induced liver disease. The results demonstrate improved indicators of liver health, reduced physical dependence, and lower standard measures of liver damage.
The daclatasvir-sofosbuvir combination was highly effective and well-tolerated in treating hepatitis C virus (HCV) patients with HIV co-infection. Across genotypes 1-4, the treatment resulted in a sustained virologic response rate of 97% at 12 weeks post-treatment.
A study published by the European Association for the Study of the Liver found that silymarin, derived from milk thistle, can resolve non-alcoholic steatohepatitis (NASH) and improve fibrosis in patients. The results suggest a potential new treatment option for this condition.
A new survey found that nearly half of people with viral hepatitis have suffered some kind of discrimination, affecting their daily lives. The study highlights the devastating impact of stigma and discrimination on quality of life, particularly in family relationships and workplaces.
A large cohort study found that long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with a significant proportion of deaths coming from liver-unrelated causes. The development of hepatocellular carcinoma plays a major role in mortality.
Preliminary results show that Civacir effectively prevents hepatitis C virus (HCV) recurrence in liver transplant patients who received antiviral therapy before their operation. The study found that Civacir provides a prophylactic efficacy in preventing HCV-reinfection, reducing the risk of graft loss.
TG1050 has been shown to reach the clinical goals considered a cure for CHB, including elimination of HBsAg and seroconversion. The study achieved these goals in 30% of TG1050-injected mice, supporting the move to a first-in-man study.
A new study presented at The International Liver Congress 2015 shows that significant weight loss through lifestyle changes can improve histological features of non-alcoholic steatohepatitis (NASH). Over 10% weight loss is necessary to induce complete resolution of steatohepatitis, fibrosis, and portal inflammation.
Many European countries lack national strategies to manage chronic viral hepatitis disease surveillance, burden assessment, and intervention impact. Governments need support for developing plans, estimating the national burden, and improving surveillance systems.
A phase III study found that simeprevir-based regimens achieved high SVR12 rates in HCV genotype 4-infected patients. The study showed that response-guided therapy criteria were met by most treatment-naïve and prior-relapser patients, resulting in high SVR12 rates.
A study found that gut microbiota plays a role in the development of alcoholic liver disease, with fecal microbiota transplantation showing promise as a potential treatment. The research highlights the importance of restoring gut functionality and re-establishing intestinal flora.
The new interferon-free 3D regimen, consisting of ABT-450/R/ABT-267 and ABT-333 plus ribavirin, demonstrated consistently high cure rates across various patient types, including GT1a and compensated cirrhosis patients. The treatment achieved SVR12 rates of 96.2% in SAPPHIRE-I study participants.
Phase III study results show obeticholic acid produces meaningful biochemical improvements, including reduced ALP and bilirubin levels. The treatment also demonstrates significant clinical benefits, such as improved liver function parameters and a lower risk of liver transplantation and death.
Studies predict improved HCC patient outcomes with new diagnostic approaches. Gadoxetic acid-enhanced MRI shows higher detection sensitivity for early-stage HCC, potentially improving treatment outcomes by ensuring optimum care.
A UK study found a genetic variant associated with fatty liver disease severity in pediatric patients. Patients had low vitamin D blood levels throughout the year, and most samples were deficient or insufficient in vitamin D status compared to national health standards.
A new fixed-dose combination of sofosbuvir and ledipasvir shows high cure rates for HCV genotype 1 patients, with only mild side effects. The treatment achieves SVR12 rates of up to 99% without the use of ribavirin, which is associated with significant side effects.
Studies show sequential combination therapy with peginterferon and nucleoside analogues results in high complete response and HBsAg loss rates. Baseline HBsAg level and rate of decline during treatment predict treatment response. Adding peginterferon to entecavir enhances response rates, viral decline, and facilitates discontinuation.
SBEL1, a compound isolated from Chinese herbal medicines, has been found to inhibit hepatitis C virus (HCV) activity by approximately 90%. It blocks virus entry and inhibits IRES-mediated translation, reducing HCV protein production and RNA replication.
A new trial involving sofosbuvir demonstrated promising results for patients with recurring HCV post-liver transplant, achieving SVR12 in 62% of cases. Additionally, improvements in clinical conditions associated with hepatic decompensation and liver function tests were observed.
Researchers have discovered an immunotherapeutic approach to treating liver cancer, utilizing isolated T-cell receptors that can recognize and eliminate liver cancer cells. This new treatment option holds promise for patients with limited treatment options, including those with advanced stage HCC.
A recent study found that mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries. In 2010, there were nearly 90,000 deaths due to hepatitis C and nearly 31,000 deaths due to hepatitis B, compared to just over 8,000 deaths from HIV/AIDS.
Two studies confirmed NAFLD as an independent cardiovascular risk factor, increasing the risk of atherosclerosis and carotid plaques. Improvement in liver health through treatment is associated with a reduced risk of developing diabetes.
A novel outcome prediction model has been developed using sequentially-assessed measures to generate an individualised mortality risk prediction without liver transplantation. The model uses age, encephalopathy, and cardiovascular failure severity on admission, as well as dynamic variables, to predict non-transplanted 15-day survival.
The European Association for the Study of the Liver (EASL) has published online recommendations for managing hepatitis C, which reflect the approval of three new direct-acting antivirals. The guidelines provide best practice on key areas, including treatment indications, available drugs, and measures to improve treatment adherence. Wit...